TORONTO -- A substantial proportion of multiple myeloma patients undergoing treatment with bispecific antibodies had sustained remissions when they discontinued therapy before disease progression, ...
Rapid advances have revolutionized the treatment of multiple myeloma, providing better disease control and prolonging survival. Patients are living years longer, thanks to novel combination therapies ...
Primary plasma cell leukemia (pPCL) is a rare and highly aggressive plasma cell malignancy, often associated with complex ...
Histopathological image of multiple myoloma. Smear preparation of bone marrow aspirate stained with May-Grünwald-Giemsa procedure. It doest not represent a histopathologic image but essentially helps ...
While it’s not as well-known as, say, leukemia or melanoma, multiple myeloma is the second most common blood cancer in adults, according to the Cancer Research Institute. “Multiple myeloma is a cancer ...
Belantamab mafodotin, a BCMA-targeting ADC, is approved for relapsed/refractory multiple myeloma after two prior therapies, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback